Literature DB >> 11711053

Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.

F P Bymaster1, J F Falcone, D Bauzon, J S Kennedy, K Schenck, N W DeLapp, M L Cohen.   

Abstract

The interaction of the psychotropic agent olanzapine with serotonin 5-HT(3) and 5-HT(6) receptors was investigated. Olanzapine did not contract the isolated guinea pig ileum, but blocked contractions induced by the 5-HT(3) receptor agonist 2-methyl serotonin (2-CH(3) 5-HT) with a pK(B) value of 6.38+/-0.03, close to the affinity of the 5-HT(3) receptor antagonist ondansetron. The atypical antipsychotic risperidone (1 microM) did not significantly inhibit 2-CH(3) 5-HT-induced contractions. Olanzapine had high affinity (pK(i)=8.30+/-0.06) for human 5-HT(6) receptors in radioligand binding studies. Olanzapine did not stimulate [35S]guanosine-5'-O-(3-thio)triphosphate ([35S]GTPgammaS) binding to the G protein G(s) in cells containing human 5-HT(6) receptors, but inhibited 5-HT-stimulated [35S]GTPgammaS binding (pK(B)=7.38+/-0.16). Among other antipsychotics investigated, clozapine antagonized 5-HT(6) receptors with a pK(B)=7.42+/-0.15, ziprasidone was three-fold less potent, and risperidone, quetiapine and haloperidol were weak antagonists. Thus, olanzapine was not an agonist, but was a potent antagonist at 5-HT(6) receptors and had marked antagonism at 5-HT(3) receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711053     DOI: 10.1016/s0014-2999(01)01399-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  28 in total

1.  Distribution of serotonin receptor of type 6 (5-HT₆) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study.

Authors:  Donatella Marazziti; Stefano Baroni; Andrea Pirone; Gino Giannaccini; Laura Betti; Lara Schmid; Elena Vatteroni; Lionella Palego; Franco Borsini; Fabio Bordi; Ilaria Piano; Claudia Gargini; Maura Castagna; Mario Catena-Dell'osso; Antonio Lucacchini
Journal:  Neurochem Res       Date:  2012-01-26       Impact factor: 3.996

2.  Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.

Authors:  Sierra Vig; Laurel Seibert; Myke R Green
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-31       Impact factor: 4.553

Review 3.  Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.

Authors:  Rudolph M Navari
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

4.  Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Authors:  Rudolph M Navari; Rui Qin; Kathryn J Ruddy; Heshan Liu; Steven F Powell; Madhuri Bajaj; Leah Dietrich; David Biggs; Jacqueline M Lafky; Charles L Loprinzi
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

5.  A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.

Authors:  Rudolph M Navari; Lawrence H Einhorn; Patrick J Loehrer; Steven D Passik; Jake Vinson; John McClean; Naveed Chowhan; Nasser H Hanna; Cynthia S Johnson
Journal:  Support Care Cancer       Date:  2007-03-21       Impact factor: 3.603

6.  Comparison of the effects of antipsychotics on a delayed radial maze task in the rat.

Authors:  Mary C Wolff; J David Leander
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

7.  Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia.

Authors:  Rosaria Di Lorenzo; Alice Brogli
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 8.  Chemotherapy-induced nausea and vomiting: optimizing prevention and management.

Authors:  Kamakshi V Rao; Aimee Faso
Journal:  Am Health Drug Benefits       Date:  2012-07

9.  The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors:  Rudolph M Navari; Cindy K Nagy; Sarah E Gray
Journal:  Support Care Cancer       Date:  2013-01-12       Impact factor: 3.603

10.  Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.

Authors:  Rudolph M Navari; Marie C Brenner
Journal:  Support Care Cancer       Date:  2009-09-11       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.